Physician and patient messaging will be key as several new pipeline agents prepare to enter the RA market. On the eve of the potential approval of Regeneron/Sanofi's sarilumab, respondents emphasize the importance for the sarilumab launch team to focus on distinguishing the IL-6 agent from Roche/Genentech's Actemra, and also propose that a competitive pricing strategy is implemented to ensure appropriate and rapid uptake. Indeed, the majority of respondents, after viewing a sarilumab product profile, do not see a difference in performance between sarilumab and Actemra with regard to efficacy, tolerability, safety, or ease of administration. Despite a need for differentiation in a busy biologics market, 95% of respondents intend to trial sarilumab within the first year of launch.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
For more information contact:
Lynn Price, Immunology Franchise Head
Logo - http://photos.prnewswire.com/prnh/20160919/409472LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/direct-to-consumer-campaigns-for-pfizers-xeljanz-abbvies-humira-and-amgens-enbrel-the-most-influential-with-ra-patients-300350933.html
SOURCE Spherix Global Insights